Adcentrx Therapeutics develops protein conjugate therapeutics that combine the targeting precision of biologics with the efficacy of small molecule payloads to treat cancer and other life-threatening diseases. The company focuses on creating targeted therapies that enhance treatment options for patients with advanced solid tumors.
Funding
$101M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ERFounders
Product
Problem
Many cancer treatments lack precise targeting, leading to systemic toxicity and reduced efficacy, especially in advanced solid tumors. Traditional approaches often fail to deliver sufficient concentrations of therapeutic agents directly to tumor cells, limiting their impact on disease progression.
Solution
Adcentrx Therapeutics is developing protein conjugate therapeutics that combine the targeting capabilities of biologics with the cytotoxic power of small molecule payloads. This approach aims to enhance treatment options for patients with advanced solid tumors by creating targeted therapies that selectively deliver potent drugs directly to cancer cells, minimizing off-target effects and maximizing therapeutic impact. Their lead candidate, ADRX-0706, is a Nectin-4 ADC currently in Phase 1b clinical trials. ADRX-0405, a STEAP1-targeting ADC, has received FDA clearance for an Investigational New Drug Application and is being developed as a potential first-in-class treatment for advanced solid tumors.
Target Audience
The primary target audience includes patients with advanced solid tumors who have limited treatment options, as well as oncologists and medical professionals seeking more effective and targeted therapies.
Features
- Protein conjugate platform combining biologics for targeted delivery and small molecule payloads for cytotoxic effect.
- ADRX-0706: Nectin-4 ADC in Phase 1b clinical trials.
- ADRX-0405: STEAP1-targeting ADC with FDA IND clearance.
- Designed to selectively target and kill cancer cells while sparing healthy tissue.
- Aims to improve treatment outcomes for patients with advanced solid tumors.